Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).
Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavon M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marino M, Zucali PA; TYME network collaborators. Imbimbo M, et al. Among authors: garassino mc. Cancer Treat Rev. 2018 Dec;71:76-87. doi: 10.1016/j.ctrv.2018.10.001. Epub 2018 Oct 5. Cancer Treat Rev. 2018. PMID: 30366202
Bevacizumab for non-small-cell lung cancer.
Garassino MC, Hollander L, Torri V. Garassino MC, et al. N Engl J Med. 2007 Mar 29;356(13):1373; author reply 1374-5. doi: 10.1056/NEJMc070042. N Engl J Med. 2007. PMID: 17392310 No abstract available.
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
Pietrantonio F, Garassino MC, Torri V, de Braud F. Pietrantonio F, et al. Among authors: garassino mc. Ann Oncol. 2012 Oct;23(10):2771-2772. doi: 10.1093/annonc/mds332. Epub 2012 Aug 8. Ann Oncol. 2012. PMID: 22875835 Free article. Clinical Trial. No abstract available.
To target or not to target, that is the question.
Garassino MC, Platania M, Broggini M, Torri V, De Braud F. Garassino MC, et al. J Clin Oncol. 2013 Mar 20;31(9):1254. doi: 10.1200/JCO.2012.45.9818. Epub 2013 Jan 28. J Clin Oncol. 2013. PMID: 23358979 Free article. No abstract available.
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Agustoni F, Platania M, Vitali M, Zilembo N, Haspinger E, Sinno V, Gallucci R, de Braud F, Garassino MC. Agustoni F, et al. Among authors: garassino mc. Cancer Treat Rev. 2014 Feb;40(1):197-203. doi: 10.1016/j.ctrv.2013.05.005. Epub 2013 Jul 10. Cancer Treat Rev. 2014. PMID: 23850197 Free article. Review.
Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M. Gelsomino F, et al. Among authors: garassino mc. Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Crit Rev Oncol Hematol. 2014. PMID: 24355409 Review.
Targeted therapy-induced diarrhea: A review of the literature.
Pessi MA, Zilembo N, Haspinger ER, Molino L, Di Cosimo S, Garassino M, Ripamonti CI. Pessi MA, et al. Crit Rev Oncol Hematol. 2014 May;90(2):165-79. doi: 10.1016/j.critrevonc.2013.11.008. Epub 2013 Dec 5. Crit Rev Oncol Hematol. 2014. PMID: 24373918 Review.
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
Haspinger ER, Garassino MC, Torri V, Cinquini M, De Braud F, Gelsomino F. Haspinger ER, et al. Among authors: garassino mc. J Clin Oncol. 2014 Mar 10;32(8):859-63. doi: 10.1200/JCO.2013.52.8794. Epub 2014 Feb 3. J Clin Oncol. 2014. PMID: 24493720 Free article. No abstract available.
252 results